AbstractRecent studies have identified disrupted‐in‐schizophrenia‐1 (DISC1) as a strong genetic risk factor associated with schizophrenia. Previously, we have reported that a mutation in the second exon of the DISC1 gene [leucine to proline at amino acid position 100, L100P] leads to the development of schizophrenia‐related behaviors in mice. Glycogen synthase kinase‐3 (GSK‐3) is a serine/threonine protein kinase that interacts with the N‐terminal region of DISC1 (aa 1–220) and has been implicated as an important downstream component in the etiology of schizophrenia. Here, for the first time, we show that pharmacological and genetic inactivation of GSK‐3 reverse prepulse inhibition and latent inhibition deficits as well as normalizing the hyperactivity of Disc1‐L100P mutants. In parallel to these observations, interaction between DISC1 and GSK‐3α and β is reduced in Disc1‐L100P mutants. Our data provide genetic, biochemical, and behavioral evidence for a molecular link between DISC1 and GSK‐3 in relation to psychopathology and highlights the value of missense mutations in dissecting the underlying and complex molecular mechanisms of neurological disorders. Synapse, 2010. © 2010 Wiley‐Liss, Inc.